Halozyme Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript

Halozyme Therapeutics (HALO)

Q2 2012 Earnings Call

August 06, 2012 4:30 pm ET


Anne Erickson

Gregory I. Frost - Co-Founder, Chief Executive Officer, President and Director

Kurt A. Gustafson - Chief Financial Officer, Principal Accounting Officer, Vice President and Secretary


John S. Sonnier - William Blair & Company L.L.C., Research Division

Jason N. Butler - JMP Securities LLC, Research Division

Christopher Holterhoff - Oppenheimer & Co. Inc., Research Division

Daniel Chung - Jefferies & Company, Inc., Research Division

Ying Huang - Barclays Capital, Research Division



Greetings, and welcome to the Halozyme Therapeutics Second Quarter 2012 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, Anne Erickson, Executive Director of Investor Relations at Halozyme Therapeutics. Thank you, Ms. Erickson. You may begin your conference.

Anne Erickson

Good afternoon. Thank you for joining Halozyme's quarterly update conference call. With me on the call today are Gregory Frost, President and Chief Executive Officer; and Kurt Gustafson, Chief Financial Officer.

This afternoon, Halozyme released second quarter 2012 financial results. If you've not received this news release or if you'd like to be added to the company's distribution list, please e-mail me at aerickson@halozyme.com.

This call is also being webcast live over the Internet at www.halozyme.com, and a replay will be available on the company's website for the next 14 days.

Before we begin, let me remind you that during this conference call, we will be making forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides the Safe Harbor for forward-looking statements. All statements made during this conference call that are not statements of historical fact constitute forward-looking statements. The matters referred to in forward-looking statements could be affected by the risks and uncertainties of Halozyme's business, both known and unknown. Such risks inherent in the company's business are described in our filings with the Securities and Exchange Commission, as well as in our news releases. The company's actual results may differ materially from those expressed in or indicated by such forward-looking statements.

If you liked this article you might like

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Good Stocks Are There for the Picking

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme